Search
Sacituzumab govitecan
go.drugbank.com/drugs/DB12893ApprovedInvestigational[A193653] Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. … [A193653] In November 2021 and July 20 2023, sacituzumab govitecan was also approved by the European Commission and Health Canada respectively.[L39372,L47601]
Eucalyptus oil
go.drugbank.com/drugs/DB11114ApprovedIt is shown to be effective in reducing pain, swelling, and inflammation via its modulatory effect on the immune response. … It is also shown to exhibit antibacterial activity against some bacterial species and cough suppressant actions.
Mixtures: Cellzyme ON-TOX, Cellzyme ON-TOXNazartinib
go.drugbank.com/drugs/DB16250InvestigationalNazartinib is under investigation in clinical trial NCT03529084 (Phase III Study of Nazartinib (EGF816) Versus Erlotinib/gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating
Finafloxacin
go.drugbank.com/drugs/DB09047ApprovedWithdrawnFinafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014. … Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.
Categories: Topoisomerase II InhibitorsCalfactant
go.drugbank.com/drugs/DB06415ApprovedInvestigationalIt is an off-white suspension of an extract of natural surfactant from calf lungs suspended in 0.9% saline. … Calfactant is approved for use in the United States of America. It is used to prevent or treat respiratory distress syndrome in premature infants with lung surfactant deficiency.
Flibanserin
go.drugbank.com/drugs/DB04908ApprovedInvestigationalFlibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. … in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters.
Daprodustat
go.drugbank.com/drugs/DB11682ApprovedInvestigational[A254172] In June 2020, daprodustat was first approved in Japan for the treatment of renal anemia. … [A254157] A phase 3 clinical trial (NCT02879305) found that in patients with CKD undergoing dialysis, daprodustat was non-inferior to erythropoiesis-stimulating agents regarding the change in the hemoglobin
Synonyms: Glycine, N-((1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl)-Polyethylene glycol 400
go.drugbank.com/drugs/DB11077ApprovedInvestigationalIt is used in ophthalmic solutions for the relief of burning, irritation and/or discomfort that follows dryness of the eye [L1785]. … It is very hydrophilic, which renders it a useful ingredient in drug formulations to augment the solubility and bioavailability of weakly water-soluble drugs.
Mixtures: i-Drops LUBRICANT EYE DROPS, i-Drops LUBRICANT EYE DROPSCategories: Compounds used in a research, industrial, or household settingPorfimer sodium
go.drugbank.com/drugs/DB00707ApprovedInvestigationalIt is the first drug to be approved in the use of photodynamic therapy in the United States. … It is used in photodynamic therapy (hematoporphyrin photoradiation); to treat malignant lesions with visible light and experimentally as an antiviral agent.
Categories: Sensitizers Used in Photodynamic/radiation TherapyInternational brands: Photofrin IIRespiratory syncytial virus vaccine, adjuvanted
go.drugbank.com/drugs/DB17762ApprovedInvestigational[L46352] It was also later approved by Health Canada on August 4, 2023,[L47666] and the EMA in March 2025.[L52380] … It comprises lyophilized recombinant respiratory syncytial virus glycoprotein F (RSVPreF3) stabilized in pre-fusion conformation as the antigen component, which is reconstituted at the time of use with